FGFR inhibitors have been tested in clinical trials to treat aggressive cancers harboring alterations in FGFR genes, including cases with FGFR1 alterations, with only partial responses and in some cases severe adverse events (Pant et al, 2023; Subbiah et al, 2022). The gene discussed is FGFR1; the disease is cancer.